INTRODUCTION AND OBJECTIVEHippotherapy (HPOT) and hippotherapy simulators (SHPOT) are used in children with cerebral palsy to achieve their maximum functionality and independence. The aim is to find out if HPOT and SHPOT produce the same effects on balance, gross motor function, and postural control in children under 18 years old with cerebral palsy.MATERIALS AND METHODSThe keywords used were: hippotherapy, equine-assisted therapy and cerebral palsy. The databases used were PeDro, Scopus, LILACS, ScienceDirect, Cochrane Library, Web of Science and CINAHL Complete (Ebsco). Studies were included if they were randomized clinical trials that studied the effect of HPOT and/or SHPOT on the variables mentioned in these patients.RESULTSFour studies assessed balance, 4 studied gross motor function, and 2 investigated postural control. Both HPOT and SHPOT produced benefits in all of them.CONCLUSIONSAccording to the studied variables both interventions produce similar improvements. Although, they increase with HPOT possibly due to greater sensory stimulation.

02 Nov 2023·Physiotherapy Theory and PracticeQ4 · MEDICINE

Clinical application and feasibility of utilizing the PEDI-CAT to assess activity and participation among children receiving physical therapy incorporating hippotherapy

Q4 · MEDICINE

Article

Author: Grant-Beuttler, Marybeth ; Evans, Trish ; O Mahony, Erin ; Beuttler, Richard ; Conroy, Susan ; Robinson, Janelle ; Huebert, Matt ; Butler-Moburg, Dana

BACKGROUNDHippotherapy (HPOT) is a physical therapy (PT) treatment tool using equine movement to improve mobility for children with movement impairments. Although research suggests HPOT improves body structure and function, there is limited evidence regarding its impact on activity and participation outcomes in a clinical setting. The Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT) may be useful in HPOT settings to highlight changes in activity and participation.PURPOSE1) Evaluate the PEDI-CAT's sensitivity to changes in activity and participation among children receiving PT using HPOT; 2) determine feasibility of administering the PEDI-CAT in a HPOT setting; and 3) examine how PEDI-CAT scores influence clinical decision-making.METHODSParticipants (N = 34) were children who attended weekly PT using HPOT for 6 months. The PEDI-CAT was completed for all participants by a parent or caregiver at initial treatment (T1) and 6 months later (T2). A linear mixed effects model was used to evaluate changes in scores over time. Team meetings occurred monthly to discuss how PEDI-CAT scores impacted treatment.RESULTSThere were significant improvements across 3 PEDI-CAT domains between T1 and T2 for all children with small effect sizes and nonsignificant changes noted within two diagnostic subgroups with small-to-medium effect sizes. The PEDI-CAT was completed by all participants without interrupting treatment flow. PEDI-CAT score reports enriched therapist-client conversations increasing shared decision-making.CONCLUSIONPTs who treat children using HPOT may feasibly use the PEDI-CAT to assess changes in activity level outcomes and to assist clinical decision-making.

01 Dec 2007·Journal of EthnopharmacologyQ2 · MEDICINE

Ostreae Testa prevent ovariectomy-induced bone loss in mice by osteoblast activations

Q2 · MEDICINE

Article

Author: Sook Jahr Park ; Sang Yeob Han ; Young Kyu Kwon ; Jong Rok Lee ; Sae Kwang Ku ; Mi Jeong Jo ; Sang Chan Kim ; Hyeung Sik Lee

AIM OF THE STUDYThe anti-osteoporotic effect of heated powder of Ostreae Testa (hPOT), a powder of oyster shell-Ostrea gigas Thumb (Ostrediae) was observed in vitro and in vivo.MATERIALS AND METHODSThe effects on proliferation and alkaline phosphatase activity of primary osteoblasts, bone nodule formation, pit formation of osteoclasts and osteoclastogenesis were observed in vitro, and to observe the in vivo efficacy hPOT was orally administered once a day for 28 days to bilateral ovariectomy-induced osteoporosis mice at 125, 250 and 500mg/kg (of body weight).RESULTSAlthough hPOT did not influence the pit formation and the number of multinucleated osteoclast-like cells, osteoclastogenesis, it enhanced the proliferation of primary osteoblasts, differentiation (ALP activity) and bone nodule formation of osteoblast in vitro. The estrogen-deficient osteoporotic changes were dramatically prevented by hPOT treatment except for osteoclasts/bone perimeter.CONCLUSIONSIn conclusion, hPOT prevents OVX-induced osteoporosis through osteoblasts activation effects.

100 Deals associated with HPOT

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Postpartum Hemorrhage	Preclinical	Japan	Kanazawa University	09 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

HPOT

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation